Abstract

Background

COVID-19 has caused a global pandemic characterized by severe pneumonia. Brain structure abnormality has been confirmed in COVID-19 patients in the UK biobank [1]. However, it is not clear whether this abnormality is reversible nor if the abnormality could be detected in the early stage of the disease.

Aims & Objectives

In this study, the pathological effect of COVID-19 on the brain integrity was monitored through the utilization of a brain injury bioindicator, neurofilament light chain (NFL) [2]. It can be released from the brain into the peripheral blood when the brain neuronal axon is injured [3]. The study aimed to assess the correlation between the discharge diagnoses and NFL levels in COVID-infected patients.

Method

Plasma samples from the National Health Research Institutes (NHRI) Biobank of 400 COVID-19 patients recruited from 24 hospitals across Taiwan were used for NFL analyses by immunoassay.

Results

Among the successfully analyzed 394 patients, 10 patients (2.5%) showed an NFL level above 200 pg/ml. The mean NFL levels were significantly higher in patients older than 50 years (P <0.0001). Male patients had a higher NFL level than females (P = 0.008). The increase in plasma levels of NFL was the highest in the first 1-7 days after the COVID-19 diagnosis was confirmed, then gradually decreased within a month. Significant higher NFL levels were observed in patients with hospitalization, respiratory or ICU treatment, and oxygen therapy (P <0.0001). Moreover, higher NFL levels were also correlated with discharge diagnoses of cardiovascular, lung, kidney, and other chronic diseases (P ≦ 0.008).

Discussion & Conclusion

COVID-19 infection may cause brain neuronal injury especially in male patients older than 50 years. In addition, the plasma NFL level was associated with a number of clinical features. The results demonstrated that NFL could be an indicator for assessing the brain neuronal integrity following COVID- 19 infection.

References

1.Douaud, G., et al., SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature, 2022. 604(7907): p. 697-707.

2.Lee, M.K. and D.W. Cleveland, Neuronal intermediate filaments.Annual review of neuroscience, 1996. 19(1): p. 187-217.

3.Khalil, M., et al., Neurofilaments as biomarkers in neurological disorders. Nature Reviews Neurology, 2018. 14(10): p. 577-589.

This content is only available as a PDF.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [email protected] for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact [email protected].